Datapoint: FDA Approves TG Therapeutics’ MS Antibody Briumvi

The FDA on Dec. 28 approved TG Therapeutics, Inc.’s Briumvi for the treatment of relapsing forms of multiple sclerosis. The monoclonal antibody will be the third anti-CD20 therapy in the relapsing MS market basket, joining Roche’s Ocrevus and Novartis’ Kesimpta. Briumvi boasts a novel administration, however — a one-hour infusion every six months following its four-hour starting dose. For the treatment of MS, Ocrevus holds covered or better status for 66% of all insured lives under the pharmacy benefit and 92% of lives under the medical benefit. Kesimpta, meanwhile, holds covered or better status for 85% of insured lives under the pharmacy benefit, and 13% of lives under the medical benefit.

SOURCE: MMIT Analytics, as of 1/9/23

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
March 28

Datapoint: FDA Approves Merck’s Winrevair

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
March 27

Datapoint: Elevance to Acquire Kroger Specialty Pharmacy

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
March 26

Datapoint: Exchange Sign-Ups See 31% Annual Increase

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today